People · Operator

Rosemina Merchant

Named in public records as an officer, director or promoter · active 2016–2024 · Biotechnology, Pharmaceuticals

2
Companies
2
Filings
$24.5M
Combined raised · real
Serial
Operator type
Companies
CompanyRoleSectorStageRaised · realValue · estTied
Medicenna Therapeutics Corp.BiotechnologySeries A$23.8M$82.9M2024
Medicenna Therapeutics Inc.PharmaceuticalsSeed$742K$28.2M2016
Operator network

Rosemina Merchant at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.

Elizabeth Williams · 9 companies · 1 sharedElizabeth WilliamsDavid Hyman · 3 companies · 1 sharedDavid HymanCHANDRA PANCHAL · 2 companies · 1 sharedCHANDRA PANCHALKaren Dawes · 2 companies · 1 sharedKaren DawesAlbert Beraldo · 1 companies · 1 sharedAlbert BeraldoALBERT G. BERALDO · 1 companies · 1 sharedALBERT G. BERALDOANDREW G. STRONG · 1 companies · 1 sharedANDREW G. STRONGJohn Geltosky · 1 companies · 1 sharedJohn GeltoskyJohn Sampson · 1 companies · 1 sharedJohn SampsonKAREN G. DAWES · 1 companies · 1 sharedKAREN G. DAWESROSEMINA G. MERCHANT · 1 companies · 1 sharedROSEMINA G. MERCH…FAHAR MERCHANT · 3 companies · 2 sharedFAHAR MERCHANTMedicenna Therapeutics Corp. · $23.8M raisedMedicenna Therapeutic…Medicenna Therapeutics Inc. · $0.7M raisedMedicenna Therapeutic…Rosemina MerchantRM
Rosemina Merchant Company Co-operator (ring = serial)Hover to isolate ties · click to open
Co-operators (shared boards)

People named alongside Rosemina Merchant on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.

OperatorSharedTheir companies
FAHAR MERCHANT23
Elizabeth Williams19
David Hyman13
Karen Dawes12
CHANDRA PANCHAL12
ALBERT G. BERALDO11
ANDREW G. STRONG11
ROSEMINA G. MERCHANT11
John Sampson11
Albert Beraldo11
John Geltosky11
KAREN G. DAWES11

People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.